DBV Technologies’ (DBVT) Buy Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday morning,Benzinga reports. They currently have a $51.00 target price on the stock.

A number of other equities analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a report on Wednesday, December 17th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. Citizens Jmp increased their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research note on Wednesday, December 17th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Stock Performance

DBVT opened at $20.00 on Friday. The stock has a market capitalization of $1.11 billion, a PE ratio of -3.83 and a beta of -0.97. DBV Technologies has a one year low of $5.30 and a one year high of $26.18. The business’s 50 day moving average price is $21.58 and its 200 day moving average price is $17.33.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, March 26th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.96). DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The business had revenue of $0.64 million for the quarter, compared to analyst estimates of $1.06 million. As a group, equities research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently modified their holdings of DBVT. Vivo Capital LLC acquired a new position in DBV Technologies during the 2nd quarter worth about $9,659,000. MPM Bioimpact LLC purchased a new position in DBV Technologies during the 2nd quarter valued at about $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies in the 2nd quarter valued at about $9,659,000. Octagon Capital Advisors LP acquired a new position in DBV Technologies in the 2nd quarter valued at about $9,315,000. Finally, New York State Common Retirement Fund purchased a new stake in DBV Technologies during the third quarter worth about $34,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.